sales@scalarmarketresearch.com  |   +1-800-213-5170  (U.S./ Canada Toll-free)  |  REGISTER |  SIGN IN

Home >> Reports >> cardiovascular diseases market

report

Cardiovascular Diseases Market, by Mechanism of Action (Calcium Channel Blocker, Rennin Inhibitors, Sodium Channel Blockers, Vasodilator, Diuretics, Thrombolytic, Beta Blocker, Beta Agonist, Alpha Blocker and Alpha Agonist), Diseases (Stroke, Hypertension, Dyslipidemia) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022

HC145 October 2016 100+ FREE 10% CUSTOMIZATION

The global cardiovascular diseases market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the cardiovascular diseases market.

KEY BENEFITS OF THE REPORT

  • Extensive evaluation of all the market dynamics that will impact this market during the forecast period
  • Granular understanding of the historical market trend and the resultant market forecast
  • Deeper understanding of the behavior of the key players and innovators influencing this market

KEY PREMIUM INDUSTRY INSIGHTS

  • The cardiovascular diseases market is expected to grow at a healthy rate due to the increasing prevalence of the cardiovascular diseases.
  • The rise in the number of aging population and the diabetic patients, along with the rise in the health problems resulting from obesity and unhealthy lifestyles will boost the cardiovascular diseases market growth in the near future.
  • The rapid technological advancements and the increasing number of new drugs under clinical trials are some of the other key factors driving the growth of the market for cardiovascular diseases.
  • Various advanced cardiac devices, such as balloons, eluting stents, and drug eluting vascular grafts used for drug delivery, are also expected to witness a significant rise in the market.
  • The major challenges faced by the pharmaceutical companies in this market include the development of the drugs, which can be used for the broader applications.
  • The decline in the number of cardiac surgeries and the high costs associated with the surgeries are also some of the major restraints for the cardiovascular disease market.
  • Due to the advancements in the pharmacotherapy with the statin therapy, beta-blockers, and ACE inhibitors; the number of cardiac surgeries has declined, which has affected the growth of this market.

RESEARCH METHODOLOGY

The research methodology for Scalar Market Research’s cardiovascular diseases market report utilizes a combination of top-down and bottom-up research formats. Our primary focus on continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensures high-quality data that can be leveraged for actionable research insights.

To know about the assumptions considered for the study, Download PDF Sample.

MARKET SEGMENTATION

This report analyzes the cardiovascular diseases market by the following segments:

  • Cardiovascular Diseases Market, by Mechanism of Action
    • Calcium Channel Blocker
    • Rennin Inhibitors
    • Sodium Channel Blockers
    • Vasodilator
    • Diuretics
    • Thrombolytic
    • Beta Blocker
    • Beta Agonist
    • Alpha Blocker
    • Alpha Agonist
  • Cardiovascular Diseases Market, by Disease
    • Stroke
    • Hypertension
    • Dyslipidemia

KEY MARKET PLAYERS

Key players in the cardiovascular diseases market include:

  • Pfizer, Inc.
  • AstraZeneca
  • Merck & Co.
  • Sanofi S.A
  • Daiichi Sankyo Company Limited
  • Bayer AG
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Astellas Parma, Inc.
  • Johnson & Johnson
  • United Therapeutics Corporation
  • Boehringer Ingelheim GmbH
  • Actlion Pharmaceuticals Ltd
  • Roche Holding AG

GEOGRAPHIC COVERAGE AND ANALYSIS

This granular market research report covers the following geographic regions in great detail:

Cardiovascular Diseases Market

TRENDING RELATED REPORT

Cardiovascular Devices Market, by Diagnostic & Monitoring (ECG, Event Monitors, Holter Monitors, Implantable Loop Recorders, Diagnostic Catheters, Echocardiogram, PET Scan, MRI, Cardiac CT, Myocardial Perfusion Scans, Doppler Fetal Monitor), Surgical (Pacemakers, Stents, Catheters & Accessories, Guidewires, Cannula, Electrosurgical Procedures, Valves, Occlusion Devices) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022


  1. EXECUTIVE SUMMARY
    1. Research Scope
      1. Market Definition / Segmentation
      2. Research Methodology
    2. Executive Summary
  2. MARKET DYNAMICS
    1. Drivers
    2. Restraints
    3. Opportunities
    4. Future Outlook
  3. INDUSTRY ANALYSIS
    1. Value Chain
    2. Patent Analysis/Reimbursement Landscape
    3. Product Roadmap
    4. Market Opportunities
    5. Geographic Growth Opportunities
  4. CARDIOVASCULAR DISEASES MARKET, BY MECHANISM OF ACTION
    1. Introduction
    2. Calcium Channel Blocker
    3. Rennin Inhibitors
    4. Sodium Channel Blockers
    5. Vasodilator
    6. Diuretics
    7. Thrombolytic
    8. Beta Blocker
    9. Beta Agonist
    10. Alpha Blocker
    11. Alpha Agonist
  5. CARDIOVASCULAR DISEASES MARKET, BY DISEASE
    1. Introduction
    2. Stroke
    3. Hypertension
    4. Dyslipidemia
  6. CARDIOVASCULAR DISEASES MARKET, BY GEOGRAPHY
    1. Introduction
    2. North America
      1. U.S.
      2. Canada
    3. Europe
      1. France
      2. Germany
      3. U.K
      4. Rest of Europe
    4. Asia-Pacific
      1. China
      2. India
      3. Japan
      4. Rest of APAC
    5. Rest of the World
      1. Latin America
      2. The Middle East and Africa
  7. COMPETITIVE LANDSCAPE
    1. Market Share Analysis
    2. Market Positioning of Key Players
    3. Key Innovator Companies
  8. KEY MARKET PLAYERS
    1. Pfizer, Inc.
    2. AstraZeneca
    3. Merck & Co.
    4. Sanofi S.A
    5. Daiichi Sankyo Company Limited
    6. Bayer AG
    7. Novartis AG
    8. Takeda Pharmaceutical Company Limited
    9. Astellas Pharma,Inc.
    10. Johnson & Johnson
    11. United Therapeutics Corporation
    12. Boehringer Ingelheim GmbH
    13. Actelion Pharmaceuticals Ltd
    14. Roche Holding AG
  9. SCALAR 360 DEGREE MARKET PERSPECTIVE
  10. APPENDIX
Please submit your enquiry below so our representative can get in touch with you
*
*
*
*
*
*
*

USA - CANADA TOLL FREE
+1-800-213-5170
EMAIL
sales@scalarmarketresearch.com

Benefits of Buying From Scalar

  • Unparalleled Expertise

    Our industry experts hold inimitable know-how across wide range of industry verticals

  • Assured Quality

    We deliver high-quality, real-time and data-driven industry insights to our clients

  • 24x7 Analyst Support

    We offer pre-purchase and post-purchase support from our industry experts

  • Privacy & Security

    All your personal information and confidential details are safe and secure with us